Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors

Gartlan, KH; Jaiswal, JK; Bull, MR; Akhlaghi, H; Sutton, VR; Alexander, KA; Chang, K; Hill, GR; Miller, CK; O&#39;Connor, PD; Jose, J; Trapani, JA; Charman, SA; Spicer, JA; Jamieson, SMF

Author(s): Gartlan, KH; Jaiswal, JK; Bull, MR; Akhlaghi, H; Sutton, VR; Alexander, KA; Chang, K; Hill, GR; Miller, CK; O'Connor, PD; Jose, J; Trapani, JA; Charman, SA; Spicer, JA; Jamieson, SMF;
Details: Publication Year 2022-06-10,Volume 5,Issue #6,Page 429-439
Journal Title: ACS Pharmacology & Translational Science
Publication Type: Research article
Abstract: Perforin is a key effector of lymphocyte-mediated cell death pathways and contributes to transplant rejection of immunologically mismatched grafts. We have developed a novel series of benzenesulfonamide (BZS) inhibitors of perforin that can mitigate graft rejection during allogeneic bone marrow/stem cell transplantation. Eight such perforin inhibitors were tested for their murine pharmacokinetics, plasma protein binding, and their ability to block perforin-mediated lysis in vitro and to block the rejection of major histocompatibility complex (MHC)-mismatched mouse bone marrow cells. All compounds showed >99% binding to plasma proteins and demonstrated perforin inhibitory activity in vitro and in vivo. A lead compound, compound 1, that showed significant increases in allogeneic bone marrow preservation was evaluated for its plasma pharmacokinetics and in vivo efficacy at multiple dosing regimens to establish a pharmacokinetic/pharmacodynamic (PK/PD) relationship. The strongest PK/PD correlation was observed between perforin inhibition in vivo and time that total plasma concentrations remained above 900 muM, which correlates to unbound concentrations similar to 3x the unbound in vitro IC(90) of compound 1. This PK/PD relationship will inform future dosing strategies of BZS perforin inhibitors to maintain concentrations above 3x the unbound IC(90) for as long as possible to maximize efficacy and enhance progression toward clinical evaluation.
Department(s): Laboratory Research
PubMed ID: 35711815
Publisher's Version: https://doi.org/10.1021/acsptsci.2c00009
Open Access at Publisher's Site: https://doi.org/10.1021/acsptsci.2c00009
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-10-25 06:46:46

Last Modified: 2024-10-25 06:48:14